SLC5A2 and myocardial infarction: While originally intended as a glucose-lowering alternative to metformin for patients with type II diabetes mellitus, contemporary discoveries indicate that SGLT2 inhibitors have a class effect on HF in individuals surviving an acute MI, whereas the incidence of recurrent MI is unchanged.